Non-vitamin K antagonist oral anticoagulants and sport

被引:2
|
作者
Romano, Silvio [1 ]
Salustri, Elisa [1 ]
Robles, Antonio G. [2 ]
Calo, Leonardo [2 ]
Penco, Maria [1 ]
Sciarra, Luigi [2 ]
机构
[1] Univ Aquila, Dept Life Hlth & Environm Sci, Laquila, Italy
[2] Casilino Polyclin Hosp, Dept Cardiol, Rome, Italy
来源
MINERVA CARDIOANGIOLOGICA | 2020年 / 68卷 / 02期
关键词
Pharmacologic actions; Athletes; Anticoagulants; Atrial fibrillation; FACTOR XA INHIBITOR; POTENTIALLY ARRHYTHMOGENIC CONDITIONS; ATRIAL-FIBRILLATION PATIENTS; TIME PHYSICAL-ACTIVITY; CARDIAC REHABILITATION; COMPETITIVE SPORTS; ANTITHROMBOTIC THERAPY; STROKE PREVENTION; RISK-FACTORS; DABIGATRAN;
D O I
10.23736/S0026-4725.20.05177-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Physical activity is worldwide recommended for its benefits on cardiovascular system. There is an increasing number of people of all ages that approach sport activity both as leisure time physical activity and as competitive sport. It is always more frequent the request even from older subjects and cardiac patients to be allowed to practice physical activity. Some problems could arise when these subjects present or develop pathologic conditions that require specific pharmacological treatment, in particular an anticoagulation therapy. This review focalizes on the manaaement of oral anticoagulant therapy (OAT) in patients practicing sport activity, especially due to atrial fibrillation and deep vein thrombosis, which represent two highly prevalent conditions, particularly with increasing age. Official recommendations in this field may appear limiting for patients, forbidding in the majority of cases sports at risk of trauma and consequent bleeding. These recommendations still resent the heritage of the "traditional" management of OAT, mainly represented by vitamin-K antagonists (VKAs). The non-vitamin K antagonist oral anticoagulants, with their more favorable pharmacokinetic-pharmacodynamic profile compare to VKAs, may now represent an opportunity to modify the approach to sport activity in patients with an indication to OAT. This review of the literature deals with possible strategies to overcome the present limitations for OAT subjects willing to pursue a healthy lifestyle, that include sport activity, minimizing at the same time their risk of bleeding.
引用
收藏
页码:98 / 109
页数:12
相关论文
共 50 条
  • [21] Non-vitamin K antagonist oral anticoagulants in valvular atrial fibrillation
    Basaran, Ozcan
    Dogan, Volkan
    Sahin, Cem
    Biteker, Murat
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 212 : 357 - 357
  • [22] Efficacy of non-vitamin K antagonist oral anticoagulants for Lemierre syndrome
    Kubota, Masayuki
    Daidoji, Hiroaki
    Takaya, Nobuhiro
    Tokunaga, Kurato
    Sonoo, Tomohiro
    Nakamura, Kensuke
    [J]. AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2016, 34 (10): : 2059.e3 - 2059.e5
  • [23] Combination of non-vitamin K antagonist oral anticoagulants and antiepileptic drugs
    Kurt, Semiha
    Sumbul, Orhan
    Aksoy, Durdane
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 (19) : 1572 - 1572
  • [24] Non-vitamin K antagonist oral anticoagulants and risk of liver injury
    Douros, Antonios
    Azoulay, Laurent
    Yin, Hui
    Suissa, Samy
    Renoux, Christel
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 176 - 176
  • [25] Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis
    Eiman Ghaffarpasand
    Maneli D. Tehrani
    Jolanta Marszalek
    Gerald Chi
    [J]. Journal of Thrombosis and Thrombolysis, 2018, 46 : 332 - 338
  • [26] Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease
    Mongeon, Francois-Pierre
    Macle, Laurent
    Beauchesne, Luc M.
    Bouma, Berto J.
    Schwerzmann, Markus
    Mulder, Barbara J. M.
    Khairy, Paul
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2019, 35 (12) : 1686 - 1697
  • [27] How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?
    De Caterina, Raffaele
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2016, 18 (0I) : 1 - 6
  • [28] Non-Vitamin K Antagonist Oral Anticoagulants: The Clinician's New Challenge
    Yorkgitis, Brian K.
    Zhang, Jeanette
    Rappold, Joseph F.
    [J]. JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2015, 115 (10): : 612 - 621
  • [29] Stakeholders in non-Vitamin K antagonist oral anticoagulants prescription: the case of Italy
    De Sensi, Francesco
    Paneni, Francesco
    [J]. EUROPACE, 2016, 18 (05): : 788 - 788
  • [30] Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory
    Blann, A. D.
    [J]. BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2014, 71 (04) : 158 - 167